Literature DB >> 29942224

Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis.

Michael Charlton1.   

Abstract

Entities:  

Year:  2018        PMID： 29942224      PMCID： PMC6009190     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 2.  Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Omar Massoud; Michael Charlton
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

3.  Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.

Authors:  Ryan B Perumpail; Robert J Wong; Aijaz Ahmed; Stephen A Harrison
Journal:  Dig Dis Sci       Date:  2015-08-07       Impact factor: 3.199

Review 4.  Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.

Authors:  Bérénice Charrez; Liang Qiao; Lionel Hebbard
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

Review 5.  Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.

Authors:  George Cholankeril; Ronak Patel; Sandeep Khurana; Sanjaya K Satapathy
Journal:  World J Hepatol       Date:  2017-04-18
  5 in total
  2 in total

Review 1.  A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Marinela Krizanac; Paola Berenice Mass Sanchez; Ralf Weiskirchen; Anastasia Asimakopoulos
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

Review 2.  Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease.

Authors:  Amr Dokmak; Mohammad Almeqdadi; Hirsh Trivedi; Sandeep Krishnan
Journal:  World J Hepatol       Date:  2019-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.